11.6: We welcome the reported progress against some NTDs. For others, reaching elimination and eradication goals and achieving UHC require safer, more effective, patient-friendly treatments that can be used in primary healthcare settings. Advancements in R&D – including new treatments for sleeping sickness, mycetoma, and leishmaniasis – have shown that progress is possible. We urge Member States to invest in R&D for health tools for NTDs, including through support for not-for-profit models.

11.7: Children require specific formulations of drugs, which are often delayed, if developed at all. There are knowledge gaps on the impact of medicines on females, especially those who may become or are pregnant, or are lactating, as they are often excluded from research. This leads to delays in access to treatments. We urge Member States to support and implement resolution language calling for R&D for health tools to address the medical needs of women and children.